Agenus Inc. (NASDAQ:AGEN) Q3 2020 Earnings Conference Call October 29, 2020 8:30 AM ET Company Participants Jennifer Buell - President & Chief Operating Officer Garo Armen - Chairman & Chief Executive Officer Christine Klaskin - Vice President of Finance Conference Call Participants Mayank Mamtani - B. Riley Matt Phipps - William Blair Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to the Agenus Third Quarter 2020 Conference Call and Webcast. At this time, all participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of incorporation ...

Agenus Inc. (NASDAQ:AGEN) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Jennifer Buell - President and COO Garo Armen - Chairman and CEO Bree Wilky - Director, Sarcoma Translational Research Program at University of Colorado Cancer Center Julie DeSander - VP and Head of Business Development Chuck Drake - Professor and Co-Director of the Cancer Immunotherapy Programs at New York-Presbyterian and Columbia University Dhan Chand - Head, Drug Discovery Anna Wijatyk - VP, Clinica ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of incorporation ...

Agenus Inc. (NASDAQ:AGEN) Q1 2020 Results Conference Call May 7, 2020 8:30 AM ET Company Participants Dr. Jennifer Buell - President and COO Dr. Garo Armen - Chairman and CEO Dhan Chand - Head, Drug Discovery Christine Klaskin - VP, Finance Conference Call Participants Mayank Mamtani - B. Riley Operator Good morning, ladies and gentlemen. Thank you for standing by. And welcome to the Agenus First Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Employer i ...

Start Time: 08:30 January 1, 0000 9:14 AM ET Agenus Inc. (NASDAQ:AGEN) Q4 2019 Earnings Conference Call March 12, 2020, 08:30 AM ET Company Participants Garo Armen - Chairman and CEO Jennifer Buell - President and COO Christine Klaskin - VP, Finance and Principal Accounting Officer Conference Call Participants Mayank Mamtani - B. Riley FBR Robert Andrew - William Blair Operator Good morning, ladies and gentlemen. Thank you for standing by. And welcome to the Agenus Fourth Quarter and Full Year 2019 Conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of incorpora ...